You are here

Alnylam

With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans

With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans

BioSpace

Flag link:

JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval

JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval

Fierce Pharma

John Maraganore

Flag link:

3 Rare Disease Drug Launches to Watch in 2020

3 Rare Disease Drug Launches to Watch in 2020

Motley Fool

Global Blood Therapeutics

sickle cell disease

acute hepatic porphyria

Flag link:

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

Biopharma Dive

clincial trials

Primary Hyperoxaluria

Flag link:

5 New Drug Approvals the FDA Gave Top Priority

5 New Drug Approvals the FDA Gave Top Priority

Motley Fool

Global Blood Therapeutics

Vertex Pharmaceuticals

Flag link:

FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

RAPS.org

Vertex Pharmaceuticals

Global Blood Therapeutics

Flag link:

Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

Motley Fool

Flag link:

FDA's rapid review pace nets an early approval for Alnylam's second drug

FDA's rapid review pace nets an early approval for Alnylam's second drug

Biopharma Dive

Flag link:

The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

Yahoo/Benzinga

The Medicines Company

Flag link:

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

Motley Fool

Akcea Therapeutics

Ionis Pharmaceuticals

Eidos Therapeutics

Flag link:

Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test

Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test

EP Vantage

Primary Hyperoxaluria

Flag link:

Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst

Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst

Fierce Pharma

ATTR amyloidosis

Flag link:

Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

Fierce Pharma

Flag link:

MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms

MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms

Xconomy

The Medicines Company

Flag link:

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Motley Fool

Akcea Therapeutics

Eidos Therapeutics

Flag link:

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

Xconomy

Flag link:

Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock

Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock

Endpoints

Flag link:

Alnylam posts strong Onpattro sales as competition heats up

Alnylam posts strong Onpattro sales as competition heats up

Biopharma Dive

Flag link:

Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Xconomy

Adverum Biotechnologies

Blackstone Life Sciences

Flag link:

Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III

Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III

BioCentury

acute hepatic porphyria

Flag link:

Pages